Development of a telematic pharmaceutical care app (Haemoassist) for multidisciplinary follow-up of patients with congenital coagulopathies

Expert Rev Hematol. 2023 Mar;16(3):213-226. doi: 10.1080/17474086.2023.2162497. Epub 2023 Jan 26.

Abstract

Background: Guidelines for congenital coagulopathies recommend that patients record treatment administrations and bleeding episodes to help healthcare professionals monitor the disease.

Research design and methods: We studied over two years which patient profiles (age, treatment regimen, treatment compliance) were most likely to accept the use of an app to collect this information. We validated the quality of patient-reported data by comparing it with data obtained from hospital electronic records, pharmacy dispensing records and patient interview, collected in an access database used as a reference. Patient and professional opinions were solicited through open-ended interviews.

Results: The app was used by 52% of 315 patients studied. Younger patients were the most frequent users. Patients with better treatment compliance used the app more, although data collection was incomplete for most patients. The best rated by patients were the reminders of days of administration and the minimum stock alerts at home. Healthcare professionals rated the app positively.

Conclusions: Healthcare professionals valued the app as useful for managing treatment of congenital coagulopathies. Patients need support and time to use the app and improve the quality of the data entered. Patients who used the app rated it positively. The treatment compliance improved.

Keywords: Congenital coagulopathies; adherence; app; bleeding reports; compliance; hemophilia.

MeSH terms

  • Blood Coagulation Disorders*
  • Follow-Up Studies
  • Humans
  • Mobile Applications*
  • Patient Compliance
  • Pharmaceutical Services*